# AMG420 (NCT03836053)

> Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03836053
- Phase: PHASE1
- Status: TERMINATED
- Sponsor: Amgen
- Conditions: Relapsed and/or Refractory Multiple Myeloma
- Interventions: AMG 420
- Enrollment: 23
- Primary outcome: Number of Participants With Dose-limiting Toxicities (DLTs)
- Primary outcome: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)
- Primary outcome: Number of Participants Who Experienced a Treatment-related TEAE

## Indexed commentary on AMG420 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=amg420-nct03836053